BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lekuona I, Anguita M, Zamorano JL, Rodríguez JM, Barja de Soroa P, Pérez-Alcántara F. Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain? Rev Esp Cardiol (Engl Ed) 2019;72:398-406. [PMID: 31007166 DOI: 10.1016/j.rec.2018.03.024] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Rivolo S, Di Fusco M, Polanco C, Kang A, Dhanda D, Savone M, Skandamis A, Kongnakorn T, Soto J. Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain. PLoS One 2021;16:e0259251. [PMID: 34767564 DOI: 10.1371/journal.pone.0259251] [Reference Citation Analysis]
2 Hernández Rojas Z, Dalmau Llorca MR, Aguilar Martín C, Gonçalves AQ, Casajuana M, Fernández-Sáez J, Rodríguez Cumplido D, Forcadell Drago E, Carrasco-Querol N, Pepió Vilaubí JM, Alegret JM. Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation: A study protocol using Real-World Data from Catalonia (FantasTIC Study). Medicine (Baltimore) 2020;99:e22054. [PMID: 32899067 DOI: 10.1097/MD.0000000000022054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]